“…The last decade of neuroproteomics research has resulted in a wealth of information on CNS protein profiles, and the proteomes of microglia [96,102,107,110,252], astrocytes [39,74,206,[253][254][255][256][257][258], and of other glial cell types [259][260][261][262][263] have been extensively analyzed with the intent of discovering biomarkers and therapeutic targets for CNS disorders. Glial proteins that are being studied as potential novel biomarkers include pentraxin-3 [102], serum amyloid A [264], cathepsin D [265], chitinase 3-like 1 (CHI3L1) [255,266], plasminogen activator inhibitor type 1 [267], metallothioneins [268], LCN2 [143,149,269], LCN-type prostaglandin D synthase, and apo D [270][271][272].…”